TP53 and colorectal carcinoma: We noted that WMJ-J-09 significantly reduces cell viability in p53-deficient HCT116 cells more efficiently than SAHA (Supplement Fig. S4B), suggesting that it may retain anti-CRC activity in tumors with p53 deficiency, a common feature in CRC and a known factor in chemoresistance.